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Little is known about comorbidities of bipolar disorder such as Parkinson’s disease. A case history and a literature survey indicate
thatbipolardisorderislinkedwithorinﬂuencesParkinson’sdiseaseandviceversa.Underlyingmechanismsarepoorlyunderstood,
and, more importantly, no treatment options are established in such double diagnoses. The few data in comorbid Parkinson cases
seem to point to a rapid cycling pattern of bipolar symptoms. With regard to therapeutic intervention, the literature supports
pramipexole for treatment of both Parkinson and depressive symptoms in bipolar depression. Lithium, the mood stabilizer of
choice for treating manic states, is problematical for use in Parkinson patients because of its side eﬀects. Valproate might be an
alternative, especially for treatment of rapid cycling.
1.Introduction
Insomecases, bipolardisorderis linkedwithParkinson’s dis-
ease. Littleis known of such comorbidities,and no treatment
options have been recommended for such exceptional cases.
Forthis paper, a MEDLINEliterature search was used. Terms
used for the search were bipolar disorder, bipolardepression,
mania, and Parkinson’s disease.
2.CaseHistory
A 69-year-old man was admitted to hospital as having a
depressive episode in Parkinson’s disease. According to his
wife, even as a young man he had often and easily become
very agitated. His wife had counted such behaviour as a
personal trait and had ordered herlife to deal with his phases
of high activity and his irritated, angry moods. When he was
in those states, which lasted a few weeks and appeared to
her to occur randomly, he had lots of ideas but he had been
able to act on them. This pattern of behaviour had lasted his
whole life until the onset of Parkinson’s disease at the age
of 61 years. The ﬁrst signs of his Parkinson’s disease were a
stiﬀness of movement of the right arm and a tremor in the
right hand. With the beginning of Parkinson’s disease, novel
behaviours, such as having depressive states and avolition,
occurred more often. In addition, the previous symptoms of
hyperactivity and angry mood became stronger. There were
also phases of hypersexuality. He also spent a lot of money.
In addition, he engaged in strenuous work in his garden,
despite the weakening of his motor abilities and physical
resilience. He labored until he was physically exhausted.
When he was cutting timber, his wife asked him to rest
for a while, but after ﬁve minutes he resumed working,
even though he felt weary. In his hyperactive state he was
not open to reasonable arguments. In contrast, there were
several days in which he was “normal” and yet other days
when he felt gloomy and had no drive. His states of mood
changed within a few days and over time worsened. Other
symptoms which occurred with his Parkinson’s disease were
forgetfulness and loss of attention. The patient’s report
of his symptoms agrees with that of his wife. He added
that usually his mood is better in the evening than in the
morning. Such mood changes over a day or in the course
of the year are not related to changes in motor function
caused by Parkinson’s disease. His Parkinson’s disease had
been treated with dopamine agonists (pramipexole, later
switched to rotigotine) at the beginning and one year later
withadditionallevodopamedication.Becauseofrecentlively
dreams accompanied by a diﬃculty in distinguishing dream
contentfromreality,theantipsychoticquetiapineinlowdose
was administered and with success. Visual hallucinations
occurredonlyonceinhislife.Thiswasafteraheartoperation2 Case Reports in Medicine
which he had undergone one year after onset of Parkinson’s
disease.
The patient’sfamily history shows an abundanceof aﬀec-
tive disorders. His mother had both a lifelong bipolar dis-
order and Parkinson’s disease in old age, just as the patient
had.Otherrelativesofthepatientalsohadaﬀectivedisorders,
but not so severe. The patient’s brother had a depressive
episode followed by a hypomanic state. Of the patient’s
two daughters, one suﬀered from recurrent depressions but
no manic states. The other daughter is described as always
overactive,having lotsofideas,buthad neverbeeninpsychic
therapy. Her symptoms did not appear to her to be serious
enough to require therapy.
3.Does Dopaminergic Medicine
Leadtothe Developmentof
Bipolar DisorderinPatients?
The history of the patient reveals cyclothymic behavioral
traits.ItissupposedthattheonsetofParkinson’sdiseasewor-
sened those traits, so that his behavior switched from “nor-
mal” to exhibiting bipolar disorder. Frequency of switches of
(hypo)mania and depression refers to “ultra-rapid cycling”.
In the literature, the inﬂuence of the dopamine system
on bipolar disorder is discussed. Manic states are related
to increased dopaminergic activity, whereas a depression is
caused by the opposite eﬀect. An experimental irritation of
the substantia nigra induces manic behaviour [1]. It is also
reported that manic behaviour appears in the on phases [2].
In that case history, the question arises whether the starting
of Parkinson medication released bipolar symptoms. On
the other hand, dopamine-2 receptor agonist pramipexole,
which was ﬁrst administered to the patient, is recommended
for therapy-resistant bipolar and unipolar depression [3].
Ingeneral, dementia,sleep disturbances, sexual malfunc-
tions, depressive episodes, dysthymia, anxiety, and panic at-
tacks occur together with Parkinson’s disease. Others report
about the possibility of development of bipolar disorder
especially in Parkinson patients: Kim et al. [4], for instance,
described two such patients with no family history of aﬀec-
tive disorders. Scappa et al. [5] reported on three patients
with rapid cycling who always had Parkinson symptoms
together with tardive dyskinesia at the beginning of a depres-
sive phase. When depression switched to mania, these symp-
toms disappeared.
In a review of literature by Goodwin and Jamison, [6]
many neurotransmitter systems, such as dopaminergic, nor-
adrenergic, serotonergic, and others, are said to be involved
in bipolar disorder but none of them alone is considered to
play a fundamental role in the development of the disease.
It is not clear how bipolar disorder and Parkinson’s disease
might inﬂuence each other, or whether they might have a
common origin.
4.IsParkinson’s Disease a Riskfor
RapidCycling?
Some case histories indicate a bipolar disorder with a rapid
cycling pattern. Rapid cycling is deﬁned being more than
four phases per year, whereas ultrarapid cycling (URC) and
ultrarapid ultradian cycling (URUC) are deﬁned by switches
within a few days and within a few hours, respectively.
Kummer et al. [7] described a sample of six Parkinson
patients with bipolar disorder. In all cases manic or hypo-
manic episodes had already appeared before the onset of
Parkinson’s disease and, furthermore, the authors supposed
that Parkinson’s diseaseacceleratesthefrequencyofepisodes.
Indeed, Kirov et al. [8] postulated a prominent role of
catechol-o-methyltransferase (COMT) in rapid cycling in
the form of lower activity of a COMT allele and polymor-
phism of serotonin transporter gene. Could COMT be a
linkage to Parkinson comorbidity? But the study had a limi-
tation: all patients also suﬀered from a comorbid DiGeorge-
syndrome. Others support polymorphism of serotonin tran-
sporter gene [9], whereas Papadimitriou et al. [10]a r g u e d
that genetic studies have not convincingly shown a genetic
determination. All in all, the question if coincidence of
Parkinson’s is a risk factor of rapid cycling has not been an-
swered yet. More data is needed.
5.TreatmentOptionsforComorbidParkinson’s
and Bipolar Patients
For the special case—the combination of Parkinson’s and
bipolar disorder—no speciﬁc data for treatment options
exist. But some remedies are known to act on both diseases,
and so it is possible to extrapolate this knowledge to that
special case. Most publications report on pramipexole. Also
reboxetine, mirtazapine, and nortriptyline are eﬀective in
treatment of depression in Parkinson patients [11]. But in
order to diminish the amount of medication and to avoid
p o s s i b l es i d ee ﬀects of additional antidepressants—because
it acts both on Parkinson symptoms and depression—pram-
ipexole is seen as an alternative to antidepressant drugs in
depressed Parkinson patients [12]. Best support of pram-
ipexole in the literature for Parkinson patients with mood
disorder is for bipolar depression [3].
Quetiapine is used as an alternative to clozapine in Par-
kinson patients with psychotic symptoms. Data also support
quetiapine for acute therapy of bipolar depression [13]a n d
as a mood stabilizer too [14]. But some studies warn of
risks to develop extrapyramidal motor symptoms (EPS)
under treatment with atypical neuroleptics. Gao et al. [15]
pointed out that bipolar patients had a higher risk for EPS
than patients with schizophrenia. In comorbid Parkinson-
bipolar disorder patients these ﬁndings are very important,
but suﬃcient data in comorbid Parkinson’s bipolar disorder
patients are needed to establish more precise treatment
options in future. An alternative mood stabilizer in bipolar-
II disorder is lamotrigine, but there are no data about
administration in comorbidity patients. In bipolar-I patients
lithium is the mood stabilizer of choice [14], but in contrast,
lithium could worsen Parkinson symptoms and causes
tremor and weakness especially. Despite of that, Kim et al.
[4] pointed out good eﬃcacy of lithium, especially when
combined with clozapine, for manic phases in comorbid
Parkinson’s bipolardisorderpatients.Inconclusion,toolittleCase Reports in Medicine 3
is known about treatment options in bipolar patients with
comorbid disease. Further investigations are needed.
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